bcr-abl peptide vaccine
Vaccineexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 1999 (NCT00004052)
Timeline
1990s
- Jan 1, 1999
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- VHL/BCR-ABL1Immunity, active
VHL/BCR-ABL1 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- bcr-abl peptide vaccine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00428077 | Phase 2 | Oct 1, 2005 | National Cancer Institute (NCI), Oregon Health and Science University |
| NCT00004052 | Phase 2 | Mar 1, 1999 | Cornell University, National Cancer Institute (NCI) |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 2 | 0 | 1 | 1999 |
| Cornell University | Academic/Hospital | 1 | 1 | 1 | 1999 |
| Oregon Health and Science University | Academic/Hospital | 1 | 1 | 1 | 2005 |
3 organizations
Page 1 / 1